Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices 50721 

Dated: September 3, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19533 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Acute Renal Injury 

Sequelae in NICU Graduates (ARISING). 

Date: October 15, 2021. 

Time: 1:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7345, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 7, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19559 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–20– 

131: Mammalian Models for Translational 

Research. 

Date: October 4, 2021. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeffrey Smiley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6194, 

MSC 7804, Bethesda, MD 20892, 301–272– 

4596, smileyja@csr.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Social Sciences and Population Studies: A 

Study Section. 

Date: October 5–6, 2021. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Suzanne Ryan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

1712, ryansj@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Musculoskeletal Tissue Engineering Study 

Section. 

Date: October 12–13, 2021. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Srikanth Ranganathan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1787, srikanth.ranganathan@nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Development—2 

Study Section. 

Date: October 12–13, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rass M. Shayiq, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

2359, shayiqr@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroscience and 

Neurodegeneration Study Section. 

Date: October 13–14, 2021. 

Time: 8:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Alessandra C. Rovescalli, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 5205, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroimmunology and Brain 

Tumors Study Section. 

Date: October 14–15, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Aleksey Gregory 

Kazantsev, Scientific Review Officer, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5201, 

Bethesda, MD 20817, 301–435–1042, 

aleksey.kazantsev@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Pathogenic Eukaryotes Study Section. 

Date: October 14–15, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tera Bounds, DVM, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3198, 

MSC 7808, Bethesda, MD 20892, 301–435– 

2306, boundst@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 19– 

367: Maximizing Investigators’ Research 

Award. 

Date: October 14–15, 2021. 

Time: 10:00 a.m. to 8:00 p.m. 


jbell on DSKJLSW7X2PROD with NOTICES
50722 Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sudha Veeraraghavan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–435–1504, 

sudha.veeraraghavan@nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Biophysics of Neural Systems 

Study Section. 

Date: October 14–15, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Geoffrey G. Schofield, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040–A, 

MSC 7850, Bethesda, MD 20892, 301–435– 

1235, geoffreys@csr.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Human 

Studies of Diabetes and Obesity Study 

Section. 

Date: October 14–15, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Hui Chen, MD, Scientific 

Review Officer, Center for Scientific Review 

National, Institutes of Health, 6701 

Rockledge Drive, Room 6164, Bethesda, MD 

20892, 301–435–1044, chenhui@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 3, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19534 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

License: Chimeric Live-Attenuated 

Vaccine for West Nile Virus (WNV) 

AGENCY: National Institutes of Health, 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Commercialization 

Patent License to practice the inventions 

embodied in the Patents and Patent 

Applications listed in the Summary 

Information section of this notice to 

Blue Water Vaccines, Inc. (BWV), 

having a place of business in Cincinnati, 

Ohio, U.S.A. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Institute of 

Allergy and Infectious Diseases’ 

Technology Transfer and Intellectual 

Property Office on or before September 

27, 2021 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

Exclusive Commercialization Patent 

License should be directed to: Peter 

Soukas, Technology Transfer and Patent 

Specialist, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, National Institutes of Health; 

Email: ps193c@nih.gov; Telephone: 

(301) 496–2644; Facsimile: (240) 627– 

3117. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

U.S. Provisional Patent Application 

Number 60/347,281, filed January 10, 

2002, PCT Patent Application Number 

PCT/US2003/00594, filed January 9, 

2003, U.S. Patent Application Number 

10/871,775 filed June 18, 2004 (now 

U.S. Patent Number 8,778,671), U.S. 

Patent Application Number 14/305,572, 

filed June 16, 2014 (now U.S. Patent 

Number 10,058,602), U.S. Patent 

Application Number 16/025,624, filed 

July 2, 2018 (now U.S. Patent Number 

10,456,461), U.S. Patent Application 

Number 16/596,175, filed October 8, 

2019 (now U.S. Patent Number 

10,869,920), U.S. Patent Application 

Number 16/952,864, filed November 19, 

2020, Israeli Patent Application Number 

162949, filed January 9, 2003 (now 

Israeli Patent Number 162949), Israeli 

Patent Application Number 209342, 

filed January 9, 2003 (now Israeli Patent 

Number 209342), Canadian Patent 

Application Number 2472468, filed 

January 9, 2003 (now Canadian Patent 

Number 2472468), Canadian Patent 

Application Number 2903126, filed 

August 27, 2015 (now Canadian Patent 

Number 2903126), Australian Patent 

Application Number 2003216046, filed 

January 9, 2003 (now Australian Patent 

Number 2003216046), Australian Patent 

Application Number 2008203442 filed 

July 31, 2008 (now Australian Patent 

Number 2008203442), Australian Patent 

Application Number 2011250694, filed 

November 10, 2011 (now Australian 

Patent Number 2011250694), Australian 

Patent Application Number 

2017203108, filed May 10, 2017 (now 

Australian Patent Number 2017203018), 

Australian Patent Application Number 

2019203166, filed May 6, 2019 (now 

Australian Patent Number 2019203166), 

Australian Patent Application Number 

2021203089, filed May 17, 2021, 

Japanese Patent Application Number 

2003–559545, filed January 9, 2003 

(now Japanese Patent Number 4580650), 

European Patent Application Number 

11000126.0, filed January 9, 2003 (now 

European Patent Number 2339011, 

validated in Belgium, Great Britain, the 

Netherlands, Norway, Germany, 

Denmark and France), entitled 

‘‘Construction of West Nile Virus and 

Dengue Virus Chimeras for use in a Live 

Virus Vaccine to Prevent Disease Cause 

by West Nile Virus,’’ [HHS Reference 

No. E–357–2001–0,1]; and U.S. and 

foreign patent applications claiming 

priority to the aforementioned 

applications. 

The patent rights in this invention 

have been assigned to the Government 

of the United States of America. 

The prospective exclusive licensed 

territory may be worldwide, and the 

field of use may be limited to: 

‘‘Chimeric Live-Attenuated Vaccines for 

West Nile Virus (WNV) for use in 

animals or humans.’’ 

West Nile virus (WNV) is a positivestrand RNA virus of the family 

Flaviviridae, part of the Japanese 

encephalitis virus serocomplex that 

includes important human pathogens 

such as Murray Valley encephalitis, 

Japanese encephalitis, and St. Louis 

encephalitis viruses. WNV has been 

present in Africa and Asia for decades 

and has usually been associated with 

mild illness that includes symptoms of 

low-grade fever, headache, rash, 

myalgia, and arthralgia. Recently, WNV 

has spread rapidly across the Western 

hemisphere and is now the major 

vector-borne cause of viral encephalitis 

in the United States. By 2010, 3 million 

adults were estimated to have been 

infected with WNV in the United States, 

with nearly 13,000 cases of 

neuroinvasive disease, almost half of 

which occurred in adults greater than 60 

years of age. In this age group, WNV 

infection can cause hepatitis, 

meningitis, and encephalitis, leading to 

paralysis, coma, and death. In 2012, 286 

people in the United States died of 

WNV, according to the U.S. Centers for 

Disease Control and Prevention (CDC). 

Preliminary data for 2013 indicate over 

1,200 cases of neuroinvasive disease 


jbell on DSKJLSW7X2PROD with NOTICES